Andrew Lowy, MD, FACS
Dr. Andrew Lowy is a world-renowned surgical oncologist who holds the title of clinical director for Cancer Surgery at UC San Diego Health’s Moores Comprehensive Cancer Center. He is an expert in pancreatic cancer surgery and the management of complex gastrointestinal cancers including malignant peritoneal mesothelioma and is skilled in the use of heated intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery.[1]
In his role as clinical director, Dr. Lowy advises on all matters relating to cancer surgery at the facility. He is also a professor in the Department of Surgery and chief of the Division of Surgical Oncology at UC San Diego School of Medicine.
Education and Career
Dr. Lowy earned his medical degree at Cornell University Medical College and completed his internship and residency training at Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He also completed a surgical fellowship at the University of Texas MD Anderson Cancer Center.[1]
Professional Memberships and Activities
Dr. Lowy is active in numerous professional medical organizations including acting as surgical liaison to the Pancreas and Hepatobiliary Committee of the Southwest Oncology Group. He was recently selected to co-chair the National Cancer Institute’s Pancreatic Cancer Task Force and serves on the editorial boards of the Journal of Clinical Oncology and the Annals of Surgical Oncology.[1]
Research
Dr. Lowy is currently the surgical principal investigator for the largest pancreatic cancer clinical trial ever conducted in the United States His research is focused on the study of pancreatic carcinogenesis and therapy, specifically on the study of the RON receptor tyrosine kinase and its role in disease pathogenesis and as a potential therapeutic target. He is also involved in model development and testing novel therapeutics. Much of his research is funded by the National Cancer Institute.[1]
Dr. Lowy is actively involved in the following clinical trials:[2]
- Pancreatic Cancer Early Detection Consortium Start Date: Sep 2020. Estimated Completion Date: Dec 2030. Recruitment Status: Recruiting. Condition(s): Pancreatic Cancer, Pancreatic Cyst, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start Date: Jul 2020. Estimated Completion Date: Nov 2030. Recruitment Status: Recruiting. Condition(s): Pancreatic Adenosquamous Carcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). Start Date: Oct 2019. Estimated Completion Date: Dec 2023. Recruitment Status: Suspended. Condition(s): Pancreatic Cancer, Pancreatic Neoplasms
His most recent publications include:[2]
A Randomized Trial of Two Remote Healthcare Delivery Models on the Uptake of Genetic Testing and Impact on Patient-reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study. Gastroenterology. 2024 Feb 04.Rodriguez NJ, Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Fortes I, Caruso A, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Zhou AY, Coffin TB, Uno H, Horiguchi M, Ocean AJ, McAllister F, Lowy AM, Klein AP, Madlensky L, Petersen GM, Garber JE, Lippman SM, Goggins MG, Maitra A, Syngal S. PMID: 38320723.
Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma – analysis from SWOG S1505. J Gastrointest Surg. 2024 Mar; 28(3):232-235. Sohal DPS, Boutin RD, Lenchik L, Kim J, Beg MS, Wang-Gillam A, Wade JL, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Chang VT. PMID: 38445914.
Intra-tumoral cell neighborhoods coordinate outcomes in pancreatic ductal adenocarcinoma. Gastroenterology. 2024 Jan 18. Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, Wade JL, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL. PMID: 38244727.
The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. JCI Insight. 2024 Jan 09; 9(1). Lumibao JC, Okhovat SR, Peck KL, Lin X, Lande K, Yomtoubian S, Ng I, Tiriac H, Lowy AM, Zou J, Engle DD. PMID: 38051586.
Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. Cancer Res Commun. 2023 10 10; 3(10):2062-2073. Semaan A, Bernard V, Wong J, Makino Y, Swartzlander DB, Rajapakshe KI, Lee JJ, Officer A, Schmidt CM, Wu HH, Scaife CL, Affolter KE, Nachmanson D, Firpo MA, Yip-Schneider M, Lowy AM, Harismendy O, Sen S, Maitra A, Jakubek YA, Guerrero PA. PMID: 37721516; PMCID: PMC10563795.
